Loading
A phase 3 trial of Tremelimumab, Rilvegostomig, Bevacizumab in hepatocellular carcinoma, run by AstraZeneca, now recruiting.
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT06921785 by AstraZeneca, with 1220 participants planned, started 2025-05-06 and due to reach its primary completion in 2030-03-15. Interventions recorded: Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Anti-angiogenic therapy.
Shares Atezolizumab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Anti-angiogenic therapy, AstraZeneca.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), AstraZeneca, Hepatocellular carcinoma.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), AstraZeneca, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/